Genomics
A foundational-CRISPR IP estate wrapped around a single, late-arriving preclinical asset (EDIT-401) — a binary 2026-2027 LDLR bet that is years behind Lilly/Verve, now fully funded into 2027+ by a May 2026 raise that diluted holders ~25%; the moat is real, the pipeline is not yet.
Research
The verdict
A foundational-CRISPR IP estate wrapped around a single, late-arriving preclinical asset (EDIT-401) — a binary 2026-2027 LDLR bet that is years behind Lilly/Verve, now fully funded into 2027+ by a May 2026 raise that diluted holders ~25%; the moat is real, the pipeline is not yet.
Editas Medicine is a clinical-stage (currently preclinical) genome-editing company built on CRISPR/Cas9 and CRISPR/Cas12a technology. It describes itself as "the only human gene editing company with a platform that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms of both… and foundational intellectual property for both" — claiming the ability to target "more than 95% of the human genome".
The business has two engines, and they are very different in quality:
An IP / royalty engine (real cash, capped). As exclusive licensee of the Broad Institute & Harvard Cas9 and Cas12a patent estates for human medicines, Editas out-licenses to others for non-dilutive capital. The marquee deal: a Dec 2023 non-exclusive license to Vertex for Cas9 use in ex-vivo BCL11A editing — i.e., Vertex's approved therapy CASGEVY. Editas received a $50.0M upfront (Q4 2023) plus annual license fees of $10.0M (2024 and 2025), with fixed + sales-based fees ranging $5.0M–$40.0M/yr through 2034. It also has a BMS/Juno collaboration (alpha-beta CAR-T / eTCR; 14 programs to date; $159.0M received in aggregate to date) and a non-exclusive Immatics license.
A drug-development engine (pre-revenue, single asset). After discontinuing its entire ex-vivo clinical program (reni-cel) in Dec 2024, the lead — and effectively only — clinical-bound asset is EDIT-401, an in-vivo, one-time CRISPR therapy to lower LDL-cholesterol by upregulating the LDL receptor (LDLR).
Customers / counterparties: Editas has no product customers (no product revenue, ever). Its economic counterparties are its licensees (Vertex, BMS/Juno, Immatics) and a royalty-monetization buyer, DRI Healthcare Trust, which in Oct 2024 paid $57.0M upfront to purchase up to 100% of the Vertex fixed/sales-based fees and a slice of the contingent payment. This last fact is load-bearing: Editas has already sold the future cash flow from the Casgevy ramp. When Casgevy sales triple in 2026 (see Lens 7), most of the upside flows to DRI, not EDIT.
Suppliers: as a preclinical biotech, key "suppliers" are its IP licensors (Broad / Harvard / MIT / Rockefeller, to whom Editas pays a "mid-double-digit percentage" of Vertex amounts on the Cas9 piece ) and a third-party LNP delivery licensor (the liver-targeting LNP used in EDIT-401, in-licensed in 2024).
Listing / size: Nasdaq "EDIT"; ~19 holders of record as of Feb 27, 2026. Market cap ~$416M at ~$2.71 (June 7, 2026), 52-wk range $1.66–$4.54. This is the small-cap laggard of the public CRISPR cohort.
A genome-editing developer's "supply chain" is its technology-input chain and its (future) manufacturing chain. Named, with chokepoints marked:
FOUNDATIONAL IP (the chokepoint that IS the company)
Broad Institute + Harvard + MIT + Rockefeller ──exclusive license──▶ EDITAS
• Cas9-I estate: rights to 85 US patents, 57 pending US apps, 37 EU patents (as of 12/31/2025)
• Editas pays Broad/Harvard a mid-double-digit % of Vertex Cas9 royalties
University of Iowa (co-owns 4 US patents w/ Broad) ──exclusive license──▶ EDITAS
│
DELIVERY TECHNOLOGY (the second chokepoint — in-licensed, not owned)
Third-party LNP licensor (liver-targeting LNP, 2024 deal) ──license──▶ EDITAS (used in EDIT-401)
Editas's own "plug 'n play" extrahepatic LNP platform (owned)
│
EDITAS ──designs guide-RNA + Cas enzyme + LNP──▶ EDIT-401 (preclinical)
│
MANUFACTURING (not yet built at scale — single-asset, early)
CDMO / third-party manufacturers (CMC) — IND/CTN-enabling material
│
CLINICAL ──first-in-human in AUSTRALIA (TGA CTN, mid-2026 target)──▶ HeFH patients
│
DOWNSTREAM ROYALTY FLOW (already sold)
Vertex (CASGEVY sales) ──fixed+sales fees──▶ EDITAS ──(sold up to 100%)──▶ DRI Healthcare Trust
BMS/Juno (14 CAR-T/eTCR programs) ──milestones──▶ EDITAS (retained)
[chain facts: research-layer: filings/10-k-2025-q4.md, Item 1 + Item 1A; CTN-in-Australia: web: StockTitan/SEC 8-K, 2026-05]
Chokepoints / single-source dependencies:
Moat 1 — Foundational IP (genuine, durable, but shared and partly monetized away). Editas's strongest asset is the exclusive human-medicine license to the Broad/Harvard Cas9 + Cas12a estates — the patent family that has now won the priority dispute against UC/Vienna/Charpentier (CVC) three times at the PTAB (most recently reaffirmed March 27, 2026). For any company commercializing CRISPR/Cas9 medicine in the US, Editas (via Broad) sits in the toll booth. This is a real, scale-and-IP moat with a ~2034–2046 patent-life runway. But: (a) the licenses Editas grants are largely non-exclusive (Vertex, Immatics), so it monetizes breadth not exclusivity; (b) much of the near-term royalty stream is sold to DRI; (c) CVC still retains the right to appeal back to the Federal Circuit, so "war over" is not yet legally true.
Moat 2 — Platform breadth (claimed, not yet productized). Cas9 + Cas12a + engineered variants + a "plug 'n play" LNP delivery toolkit is a wider toolkit than single-enzyme rivals. The "functional upregulation" approach (editing non-coding regulatory regions to increase a normal gene's expression, vs. the field's usual knockdown/correction) is genuinely differentiated and addresses diseases where knockdown fails. But a platform with zero assets in the clinic is a moat on paper. The proof-of-concept (reni-cel) was killed for commercial, not scientific, reasons.
Bargaining power: Weak as a drug developer (pre-revenue, capital-dependent, just diluted at $2.25 — Lens 5). Moderate as an IP licensor (it controls a must-have estate, but has already sold the best near-term cash flow). Net: the moat protects the patent annuity, not the equity. Whoever needs CRISPR/Cas9 needs Broad/Editas; but EDIT shareholders capture little of that because the cash was securitized and the equity value now rides almost entirely on one unproven preclinical asset.
Editas does not report product or geographic operating segments — it is a single-segment, pre-revenue R&D entity. segments.csv is empty (header-only). The only meaningful revenue decomposition is by collaboration counterparty:
| Revenue source | FY2025 | FY2024 | Note | Source |
|---|---|---|---|---|
| BMS/Juno collaboration | $23.2M (incl. $9.7M prev. deferred) | — | milestone + deferred recognition | |
| Vertex annual license fee | $10.0M | $10.0M | fixed annual fee (largely sold to DRI) | |
| Total collaboration & other R&D revenue | $40.5M | $32.3M (+25%) | lumpy; milestone-driven |
Deferred revenue (BMS) at 12/31/2025: $40.5M, all long-term. The FY25 increase was driven by recognition of remaining deferred revenue on the conclusion of a (separate) strategic-partner agreement plus a 2025 BMS milestone. Trend: not a growth line — it is timing noise. Management explicitly warns revenue "will fluctuate from quarter-to-quarter and year-to-year" on milestone/option timing. Q1-2026 collaboration revenue was just $2.8M (vs $4.7M Q1-2025).
+clinical swap — the asset table IS the company)| Program | Indication | Modality / mechanism | Phase (June 2026) | Next catalyst (date) | PoS (subjective) | Source |
|---|---|---|---|---|---|---|
| EDIT-401 | Heterozygous familial hypercholesterolemia (HeFH) → broader hyperlipidemia/ASCVD | In-vivo CRISPR/Cas9 + dual gRNA, LDLR upregulation via LNP to liver | Preclinical → first-in-human imminent | CTN filing in Australia (TGA) by mid-2026; dosing in HeFH later 2026; early human PoC by end-2026; dose-finding topline 2027 | Low-Med (mechanism de-risked in NHP; human unproven; behind competitors) | + |
| HSC in-vivo (SCD/TDT) | Sickle cell / beta-thalassemia | In-vivo AsCas12a to HBG1/2 promoter | Preclinical (de-prioritized) | none committed — "plan to focus resources on EDIT-401" | Low (resourcing deferred) | |
| Extrahepatic LNP targets | undisclosed | "plug 'n play" LNP to non-liver tissues | Discovery | in-vivo delivery shown in 2 cell types (humanized mice) | n/a | |
| BMS/Juno (partnered) | solid/liquid tumors, autoimmune | Cas9/AsCas12a edited alpha-beta CAR-T/eTCR | 14 programs; lead (CD19 HD Allo) in Phase I | partner milestones "next 12–18 months" | partner-controlled | |
| Vertex CASGEVY (licensed) | SCD/TDT | ex-vivo Cas9 BCL11A (Editas IP, not Editas's drug) | Approved & commercial | royalty, largely sold to DRI | — |
EDIT-401 preclinical profile (the entire investment case): in NHPs, a single dose drove ≥90% mean LDL-C reduction within 48 hours, with a ≥6-fold mean increase in liver LDLR protein requiring only ~10–40% functional allele editing; durable over a 3-month mouse study; well-tolerated, only transient liver-enzyme bumps that resolved in a week. May 2026 data added ~90% reductions in Lp(a) and ApoB alongside LDL-C, no adverse clinical observations or liver histopathology at the therapeutic dose. Editas received positive pre-IND FDA feedback on nonclinical, CMC, and study design — but is running the first-in-human via an Australian TGA CTN (a faster regulatory path than a US IND).
The point of Lens 5: this is a one-asset, single-shot-on-goal company. The entire equity value above the IP-annuity floor rests on whether EDIT-401's spectacular animal data replicates in humans starting late-2026 — and whether being late to the LDL party still leaves a market.
No transcripts on disk (transcripts/ empty). Reconstructed from press releases / coverage:
Tone shift over time: from breadth/platform optimism (2023, multiple ex-vivo programs) → crisis & retrenchment (Dec 2024) → narrow, milestone-disciplined, IP-defensive (2025-26). What they stopped saying: anything about commercializing reni-cel, or being a multi-program clinical company. What they keep saying: "in vivo," "functional upregulation," "human proof-of-concept by end of 2026," "best-in-class." The whole company is now a countdown to one data readout.
+clinical swap)Catalyst calendar (what de-risks or kills the thesis, and when):
| When | Event | Why it matters | Source |
|---|---|---|---|
| Mid-2026 | EDIT-401 CTN filed in Australia (TGA); additional preclinical data | gates the first-in-human start | |
| 2H 2026 | First HeFH patient dosed | execution proof; trial actually live | |
| End-2026 | Early human proof-of-concept LDL-C data | THE binary. ≥80% LDL-C drop in ≥3 patients also triggers the warrant value (Lens 5/9) | |
| 2027 | Dose-finding topline | confirms the human dose-response | |
| Ongoing | BMS/Juno partner milestones (12–18 mo) | non-dilutive cash | |
| Ongoing | CVC potential CAFC appeal of the March 2026 PTAB reaffirmation | tail risk to the IP annuity |
Mechanism comps (this is how a clinical name is valued — by competing approaches, not P/E). LDL-lowering in-vivo editing race:
| Player | Asset | Mechanism | Stage (June 2026) | Human data | Source |
|---|---|---|---|---|---|
| Eli Lilly / Verve | VERVE-102 | In-vivo base editing, PCSK9 knockdown (LNP) | Phase 1b (Heart-2) done; Phase 2 by end-2026 | −88% PCSK9, −62% LDL-C at top dose, NEJM-published | |
| Editas | EDIT-401 | In-vivo CRISPR/Cas9, LDLR upregulation (LNP) | Preclinical; first-in-human late 2026 | none yet (NHP only: ≥90% LDL-C) | |
| CRISPR Therapeutics | CTX310/320 class | In-vivo editing, ANGPTL3/Lp(a) | clinical | reported | |
| Others named by Editas | AccurEdit, nChroma, Scribe, Tune, Yoltech, EmendoBio | various | preclinical/early | — |
The comp verdict: EDIT-401 is mechanistically differentiated (upregulating LDLR rather than knocking down PCSK9 → deeper ~90% LDL-C, plus an Lp(a)/ApoB signal Verve's PCSK9 approach gets less of) and targets a different node — but it is roughly two years behind Lilly/Verve on the clinical clock, and Lilly is an infinite-balance-sheet competitor. The CASGEVY mechanism comp (Editas's own licensed IP) is now a commercial product: Vertex booked $116M FY2025 Casgevy sales (64 patients) and guides to ~$227M / ~3x in 2026 — proof the underlying Cas9 platform works in humans and sells, but Editas captures only its fixed fee (sold to DRI), not the ramp.
Valuation-multiple note: a pre-revenue, single-preclinical-asset biotech has no meaningful EV/Sales, EV/EBIT, or P/E — n/a — not applicable to a pre-revenue developer. Peers are valued on pipeline/rNPV and cash, covered in Lens 11.
EDIT is a high-beta, news-driven microcap. The pattern over the last ~18 months:
What the tape says the market actually reacts to: (1) clinical-asset existence/PoC binary events (biggest), (2) CRISPR-patent rulings (IP overhang), (3) financings/dilution. It barely reacts to the royalty/collaboration revenue line — confirming the equity is valued on the drug, not the toll booth.
insider-transactions.csv not on disk — n/a, not sourced from research layer. The May 2026 raise diluted everyone, including insiders.Editas's accounting is clean and simple by biotech standards — there is no revenue-recognition aggression to hide because there is barely any revenue, and no inventory/receivables build because there is no product.
Regulatory findings (required sub-section):
+clinical swap)The question that matters for a clinical name is not EPS — it is: does cash reach the next value-inflection catalyst? Here, comfortably yes.
Runway bridge:
rNPV sketch of EDIT-401 (the only asset with material option value):
Forecast tracker: per --watchlist unattended rules, no forecast.ts create logged (only log a committed base case outside the sweep). The natural binary to track later: "EDIT-401 first-in-human reports ≥80% mean LDL-C reduction in ≥3 patients by 2027-06-30."
Bull case. Editas is a cash-plus-IP-plus-a-free-option story trading at a microcap valuation. (1) It owns the exclusive human-medicine license to the CRISPR/Cas9 + Cas12a foundational estate that just won its patent war a third time — a multi-decade annuity and a strategic asset any large-cap CRISPR player might want (M&A optionality). (2) CASGEVY is now a real, ramping commercial product (≈$227M 2026E sales) validating that the underlying Cas9 platform works and sells in humans. (3) EDIT-401's preclinical data is genuinely best-in-class — ≥90% LDL-C, ~90% Lp(a) and ApoB reductions, clean tolerability, via a differentiated upregulation mechanism — with positive pre-IND FDA feedback and a fast Australian first-in-human path to human PoC by end-2026. (4) The May 2026 raise fully funds the company past that catalyst into 2028, and the milestone-tied warrants pre-load the upside. (5) Sell-side is constructive: Buy consensus, avg target ~$5.40–$6.00 vs ~$2.50 spot (~2x). The contrarian read: the market is so scarred by the reni-cel pivot that it is pricing EDIT near an IP-and-cash floor while handing you the EDIT-401 readout for almost free.
Bear case (2–3 things that permanently impair). (1) Single-asset binary in a race it's losing on the clock. EDIT-401 is preclinical entering humans in late 2026; Lilly/Verve's VERVE-102 already has published Phase 1b human data (−62% LDL-C) and starts Phase 2 by end-2026. A deep-pocketed competitor two years ahead can define the market, the trial bar, and the payer narrative before Editas has a single human data point. If EDIT-401's human data disappoints or merely matches a faster rival, the asset's option value collapses and the equity reverts to the (thin, DRI-encumbered) IP floor. (2) The royalty upside is already sold. The Casgevy ramp — the most tangible good news — flows mostly to DRI, not EDIT holders; the IP "floor" is worth less to the equity than headlines imply. (3) Chronic dilution at depressed prices. $1.7B accumulated deficit, repeated ATM/equity raises (the May 2026 round at $2.25, below the prior year's levels; ATM sales at a $3.07 wavg), and a sub-$5 stock mean shareholders are serially diluted to fund a single shot on goal.
Pre-mortem (it's Dec 2027 and the thesis broke): EDIT-401's first-in-human LDL-C reductions came in below the spectacular NHP numbers (human delivery/editing efficiency < primate), or showed a liver-safety signal the animals didn't, just as Verve/Lilly posted clean Phase 2 data and locked up KOLs and payers. The end-2026 "PoC" was equivocal, the warrants expired worthless, and Editas had to raise again below $2 — or put itself up for sale for little more than its DRI-encumbered IP.
Are multiples too high? Not on a multiples basis (none apply — pre-revenue). On an rNPV/option basis, the ~$416M cap is defensible-to-cheap relative to cash + IP + a real (if late) asset — the risk is binary, not valuation.
Contrarian view (what the market refuses to see): that the IP estate, not EDIT-401, may be the real asset — a strategic acquirer wanting clean foundational-Cas9 rights (now thrice-blessed by the PTAB) could pay for the toll booth and get the LDLR call option free. The market is fixated on the (losing) clinical race and underweighting the M&A floor under the patents.
Dismantling the bull case:
A David Liu-pedigreed prime-editing pioneer cornered into a defensive crouch — 25% RIF, founder-CEO out, lead CGD asset demoted to a partnering candidate, going-concern doubt at ~14 months of cash, and an existential Beam IP arbitration over one of its two surviving lead programs. At a ~$537M cap it is a deeply discounted binary call option on 2027 first-in-human liver data; bullish only for risk-seeking capital that can survive a dilution-or-bust 2026.
A real long-read/native-modification monopoly inside a structurally hard razor-and-blade model — but the market has stopped paying for "deep tech that takes 10 years"; down 73% from IPO, near 52-week lows, it is a show-me story where 2027 EBITDA breakeven (twice-pushed) is the entire thesis, and the new ex-Danaher CEO either professionalizes the commercial engine or the optionality stays un-priced.